JSJian Shen

Jian Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Shen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Victor Schally

    Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, FL 33125, USA

    1 shared publication
  • Chen-Leng Cai

    Department of Pediatrics, Indiana University School of Medicine, Indianapolis, USA

    1 shared publication
  • Christina Sanchez

    Department of Pediatrics, Herman Wells Center for Pediatric Research, Indiana University School of Medicine (J.R., L.Z., D.H., F.Y., M.S., C.S., W.S., C.-L.C.).

    1 shared publication
  • Deqiang Li

    Division of Cardiovascular Surgery, University of Maryland School of Medicine, Baltimore (D.L.).

    1 shared publication
  • Donghua Hu

    Department of Pediatrics, Herman Wells Center for Pediatric Research, Indiana University School of Medicine (J.R., L.Z., D.H., F.Y., M.S., C.S., W.S., C.-L.C.).

    1 shared publication
  • Fan Yang

    Department of Pediatrics, Herman Wells Center for Pediatric Research, Indiana University School of Medicine (J.R., L.Z., D.H., F.Y., M.S., C.S., W.S., C.-L.C.).

    1 shared publication

Latest Publications

  • Improvement of cardiac and systemic function in old mice by agonist of growth hormone‐releasing hormone

    by Pingping Xiang, Wangwei Jing, Yinuo Lin, Qi Liu, Jian Shen, Xinyang Hu, Jinghai Chen, Renzhi Cai, Joshua M. Hare, Wei Zhu, et al.

    Age‐related diseases such as cardiovascular diseases portend disability, increase health expenditures, and cause late‐life mortality. Synthetic agonists of growth hormone‐releasing hormone (GHRH) exhibit several favorable effects on heart function and remodeling. Here we assessed whether GHRH agonist MR409 can modulate heart function and systemic parameters in old mice. Starting at the age of 15 months, mice were injected subcutaneously with MR409 (10 µg/day, n = 8) or vehicle (n = 7) daily for 6 months. Mice treated with MR409 showed improvements in exercise activity, cardiac function, survival rate, immune function, and hair growth in comparison with the controls. More stem cell colonies were grown out of the bone marrow recovered from the MR409‐treated mice. Mitochondrial functions of cardiomyocytes (CMs) from the MR409‐treated mice were also significantly improved with more mitochondrial fusion. Fewer β‐gal positive cells were observed in endothelial cells after 10 passages with MR409. In Doxorubicin‐treated H9C2 cardiomyocytes, cell senescence marker p21 and reactive oxygen species were significantly reduced after cultured with MR409. MR409 also improved cellular ATP production and oxygen consumption rate in Doxorubicin‐treated H9C2 cells. Mitochondrial protein OPA1 long isoform was significantly increased after treatment with MR409. The effects of MR409 were mediated by GHRH receptor and protein kinase A (PKA). In short, GHRH agonist MR409 reversed the aging‐associated changes with respect of heart function, mobility, hair growth, cellular energy production, and senescence biomarkers. The improvement of heart function may be related to a better mitochondrial functions through GHRH receptor/cAMP/PKA/OPA1 signaling pathway and relieved cardiac inflammation.


  • Novel Myh11 Dual Reporter Mouse Model Provides Definitive Labeling and Identification of Smooth Muscle Cells—Brief Report

    by Jian Ruan, Lu Zhang, Donghua Hu, Xianghu Qu, Fan Yang, Fuxue Chen, Xiangqin He, Jian Shen, Kunzhe Dong, Megan Sweet, et al.

    Objective: Myh11 encodes a myosin heavy chain protein that is specifically expressed in smooth muscle cells (SMCs) and is important for maintaining vascular wall stability. The goal of this study is to generate a Myh11 dual reporter mouse line for definitive visualization of MYH11 + SMCs in vivo. Approach and Results: We generated a Myh11 knock-in mouse model by inserting LoxP-nlacZ-4XpolyA-LoxP-H2B-GFP-polyA-FRT-Neo-FRT reporter cassette into the Myh11 gene locus. The nuclear (n) lacZ-4XpolyA cassette is flanked by 2 LoxP sites followed by H2B-GFP (histone 2B fused green fluorescent protein). Upon Cre-mediated recombination, nlacZ-stop cassette is removed thereby permitting nucleus localized H2B-GFP expression. Expression of the nuclear localized lacZ or H2B-GFP is under control of the endogenous Myh11 promoter. Nuclear lacZ was expressed specifically in SMCs at embryonic and adult stages. Following germline Cre-mediated deletion of nuclear lacZ, H2B-GFP was specifically expressed in the nuclei of SMCs. Comparison of nuclear lacZ expression with Wnt1 Cre and Mef2c Cre mediated-H2B-GFP expression revealed heterogenous origins of SMCs from neural crest and second heart field in the great arteries and coronary vessels adjacent to aortic root. Conclusions: The Myh11 knock-in dual reporter mouse model offers an exceptional genetic tool to visualize and trace the origins of SMCs in mice.